Incidence of increased 68Ga-DOTANOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET/CT

Journal of Nuclear Medicine

Volumn 52, Issue 6, 2011, Pages 886-890

  Castellucci, Paolo ^a   Ucha, Javier Pou ^b   Fuccio, Chiara ^a   Rubello, Domenico ^c   Ambrosini, Valentina ^a   Montini, Gian Carlo ^a   Pettinato, Vincenzina ^a   Malizia, Claudio ^a   Lodi, Filippo ^a   Fanti, Stefano ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b HOSPITAL DO MEIXOEIRO   (Spain)

^c SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

68Ga DOTANOC PET CT; Biodistribution; Neuroendocrine tumors

Indexed keywords

DOTANOC GA 68; RADIOISOTOPE; UNCLASSIFIED DRUG; 68GA DOTANOC; 68GA-DOTANOC; DIAGNOSTIC AGENT; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; CLINICAL ASSESSMENT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; LIVER PARENCHYMA; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TUMOR LOCALIZATION; AGED; LIVER; METABOLISM; MIDDLE AGED; PANCREAS; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; TISSUE DISTRIBUTION;

ADULT; AGED; FEMALE; HUMANS; LIVER; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; ORGANOMETALLIC COMPOUNDS; PANCREAS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 79958124607     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.088328     Document Type: Article

References (20)

1. 68Ga-DOTA-NOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med. 2010;51:669-673.
2. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24:389-427. (Pubitemid 37056239)
3. Ugur O, Kothari PJ, Finn RD, et al. Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. Nucl Med Biol. 2002;29:147-157. (Pubitemid 34127947)
4. 18F-FDG. Cancer. 2008;112:2447-2455.
5. 68Ga-DOTA-Tyr3- octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nucl Med. 2009;50:1427-1434.
6. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumors: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2003;30:781-793. (Pubitemid 36612963)
7. Antunes P, Ginj M, Zhang H, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging. 2007;34:982-993.
8. Hofmann M, Maecke H, Börner R, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data. Eur J Nucl Med. 2001;28:1751-1757. (Pubitemid 33815052)
9. 68Ga-DOTA-NOC PET: a promising prognostic tool in neuroendocrine tumors. J Nucl Med. 2010;51:353-359.
10. 68Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging. 2010;37:67-77.
11. Gabriel M, Decristoforo C, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508-518. (Pubitemid 47571404)
12. 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med. 2009;50:1927-1932.
13. 18F-DOPA PET in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2010;37:46-48.
14. 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging. 2008;35:1431-1438.
15. 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med. 2009;50:1214-1221.
16. 68Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2010;37:722-727.
17. Kumar U, Sasi R, Suresh S, et al. Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes. 1999;48:77-85. (Pubitemid 29019355)
18. Prasad V, Baum RP. Biodistribution of Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions. Q J Nucl Med Mol Imaging. 2010;44:61-67.
19. 68Ga for medical application. J Nucl Med. 2007;48:1741-1748.
20. Elsinga P, Todde S, Penuelas I, et al; Radiopharmacy Committee of the EANM. Guidance on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 2010;37:1049-1062.